A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis by Stump, Kristine L et al.
RESEARCH ARTICLE Open Access
A highly selective, orally active inhibitor of Janus
kinase 2, CEP-33779, ablates disease in two
mouse models of rheumatoid arthritis
Kristine L Stump, Lily D Lu, Pawel Dobrzanski, Cynthia Serdikoff, Diane E Gingrich, Ben J Dugan, Thelma S Angeles
, Mark S Albom, Mark A Ator, Bruce D Dorsey, Bruce A Ruggeri and Matthew M Seavey
*
Abstract
Introduction: Janus kinase 2 (JAK2) is involved in the downstream activation of signal transducer and activator of
transcription 3 (STAT3) and STAT5 and is responsible for transducing signals for several proinflammatory cytokines
involved in the pathogenesis of rheumatoid arthritis (RA), including interleukin (IL)-6, interferon g (IFNg) and IL-12.
In this paper, we describe the efficacy profile of CEP-33779, a highly selective, orally active, small-molecule inhibitor
of JAK2 evaluated in two mouse models of RA.
Methods: Collagen antibody-induced arthritis (CAIA) and collagen type II (CII)-induced arthritis (CIA) were
established before the oral administration of a small-molecule JAK2 inhibitor, CEP-33779, twice daily at 10 mg/kg,
30 mg/kg, 55 mg/kg or 100 mg/kg over a period of 4 to 8 weeks.
Results: Pharmacodynamic inhibition of JAK2 reduced mean paw edema and clinical scores in both CIA and CAIA
models of arthritis. Reduction in paw cytokines (IL-12, IFNg and tumor necrosis factor a) and serum cytokines (IL-12
and IL-2) correlated with reduced spleen CII-specific T helper 1 cell frequencies as measured by ex vivo IFNg
enzyme-linked immunosorbent spot assay. Both models demonstrated histological evidence of disease
amelioration upon treatment (for example, reduced matrix erosion, subchondral osteolysis, pannus formation and
synovial inflammation) and reduced paw phosphorylated STAT3 levels. No changes in body weight or serum anti-
CII autoantibody titers were observed in either RA model.
Conclusions: This study demonstrates the utility of using a potent and highly selective, orally bioavailable JAK2
inhibitor for the treatment of RA. Using a selective inhibitor of JAK2 rather than pan-JAK inhibitors avoids the
potential complication of immunosuppression while targeting critical signaling pathways involved in autoimmune
disease progression.
Introduction
Inflammation acting as a driver of pathology has pre-
viously been thought to be primarily restricted to infec-
tious diseases and autoimmune disorders; however, it
has become more apparent that inflammation plays a
larger role in multiple different disease indications, such
as obesity, coronary artery disease and cancer [1,2]. Tar-
geting mediators of inflammation has received enor-
mous attention in the past decade with the advent of
biologics, most notably antibodies that capture or
neutralize disease-driving cytokines [3]. However, biolo-
gics have several disadvantages compared with orally
active small molecules, such as route of administration,
cost of production and the possibility of anaphylactic
reactions [4]. Unlike the direct targeting of cell surface
receptors or cytokines, another approach is to target
cytokine pathways by inhibiting key kinases involved in
transducing cytokine receptor signals [5]. In the present
article, we describe the preclinical evaluation of a
potent, orally active, small-molecule inhibitor of Janus
kinase 2 (JAK2), CEP-33779, for the treatment of rheu-
matoid arthritis (RA).
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primarily affects the synovial joints. RA can also produce
diffuse inflammation in the lungs and pleura and also
forms subcutaneous nodular lesions. About 1% to 2% of
the world’s population is affected by RA, and there is a
gender bias associated with disease onset. Women are
three times more likely than men to develop RA
between the ages of 35 and 50 years. Treatments for RA
have included mainly disease-modifying antirheumatic
drugs and have been more prolific than those for the
more difficult to treat rheumatic diseases, such as lupus.
Approved treatments for RA include nonsteroidal anti-
inflammatory drugs, antimetabolites such as methotrex-
ate and leflunomide, various corticosteroids and gluco-
corticoids, sulfasalazine, and various biologics, including
abatacept, adalimumab, etanercept, infliximab, golimu-
mab, and rituximab [3]. Other molecules implicated in
the pathogenesis of RA include B lymphocyte stimula-
tor/B cell activating factor, a proliferation-inducing
ligand, p38/mitogen-activated protein kinase, and the B-
cell receptor protein spleen tyrosine kinase Syk [6,7].
The recent US Food and Drug Administration approval
of tocilizumab (anti-interleukin (IL)-6R) further demon-
strates the power of targeting cytokines and associated
receptors to treat chronic inflammatory diseases [8].
Using small molecules to target cytokine pathways is
an attractive method to treat disease simply because of
the oral bioavailability of small molecules and the
reduced cost of production, thus reducing the cost car-
ried over to the patient and healthcare system as a
whole. The safety profile of antibody biologics, especially
anti-tumor necrosis factor a (anti-TNFa) antibodies, has
come under greater scrutiny over the past several years
as more and more patients and physicians have reported
problems associated with long-term use [9-11]. It is
well-documented that JAK kinases play a pivotal role in
cytokine receptor signaling to phosphorylate and acti-
vate signal transducer and activator of transcription
(STAT) proteins. Several of these JAK-controlled cyto-
kine receptor pathways are intimately involved in the
initiation and progression of RA disease pathogenesis
[12]. Cytokines involved in these diseases (for example,
interleukin (IL)-2, IL-6, IL-12, interferon g (IFNg)a n d
granulocyte macrophage colony-stimulating factor (GM-
CSF)) are also essential to a properly functioning
immune response to infectious agents. JAK1, JAK2 and
tyrosine kinase 2 (TYK2) kinases are ubiquitously
expressed, whereas JAK3 is limited to the lymphoid line-
age as JAK3 associates with the common g-chain.
The therapeutic benefit of JAK kinase inhibition has
already been established in RA with the use of CP-
690,550, a pan-JAK inhibitor originally intended for
organ transplantation immunosuppression, as it is a
potent inhibitor of JAK3 but has also been shown to
have activity against JAK1 and JAK2 [13]. More recently,
the selective JAK1/JAK2 inhibitor INCB028050 has been
shown to have efficacy in various rodent models of RA,
further demonstrating the central role that JAK kinase
plays in this disease [14]. The mechanistic rationale of
targeting cytokine pathways central to the pathogenesis
of RA, but without the immunosuppressive side effects
of several of the TNFa blockade biologics, has been
demonstrated in the successful use of tocilizumab to
treat RA [15]. The present report shows that a novel,
potent, orally active, selective JAK2 inhibitor, CEP-
33779, can ameliorate disease in two mouse models of
RA. JAK2 inhibition decreased several inflammatory
cytokines, including IL-6, IL-12, IL-1b and IFNg,b o t h
systemically and locally at the site of disease and treated
symptoms of chronic, pathological joint destruction in a
well-tolerated manner.
Materials and methods
Animals, antibodies, cell culture reagents, compounds,
cell lines
Mice used for collagen-induced arthritis (CIA) and col-
lagen-antibody induced arthritis (CAIA) studies were
Harlan female DBA/1 mice (Harlan, Somerville, NJ,
USA) Female Balb/c mice from Jackson Laboratories
(Bar Harbor, ME, USA) were used for all air pouch
model (APM) studies. Mice were age-matched 6 to 8
weeks from the start of the experiments. All animals
were maintained on a 24-hour light-dark cycle, with
food and water available ad libitum. All experimental
animal procedures were approved by, and in accordance
with the regulations of, the Institutional Animal Care
and Use Committee of Cephalon, Inc.
Compound
CEP-33779 was prepared in a manner analogous to the
five-step method described elsewhere [16]. Compound
CEP-33779 was administered orally in suspension form,
dissolved in dimethyl sulfoxide (DMSO) (1% final con-
centration) (Sigma, St. Louis, MO, USA), and further
reconstituted in PEG400 (Emerald BioSystems, Bain-
bridge Island, WA, USA) to the desired concentration
for oral administration. The compound was adminis-
tered orally through gavage tubes for all animals treated
with CEP-33779.
All spleen samples were analyzed using an Accuri C6
Flow Cytometer (Accuri Cytometers, Ann Arbor, MI,
USA). Antibodies used for Western blot analysis were
anti-phosphorylated STAT5 (Cell Signaling Technology,
Danvers, MA, USA) and anti-total STAT5 (Cell Signal-
ing Technology). Complete media (R10) was used for all
experiments involving the ex vivo culture of splenocytes
for all enzyme-linked immunosorbent spot assay (ELI-
SPOT) experiments. Complete media consisted of RPMI
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(Cellgro), 1% L-Gln (Cellgro), 1% nonessential amino
acids (Cellgro), b-mercaptoethanol (Sigma), and 10%
fetal bovine serum (Cellgro). The small-molecule JAK2
inhibitor CEP-33779 was synthesized according to pro-
cedures detailed elsewhere [16]. The cell line HEL92
(American Type Culture Collection, Manassas, VA,
USA) was used for early pharmacodynamic (PD) testing
of phosphorylated STAT5 (pSTAT5) inhibition using
CEP-33779.
Western blot analysis
Samples were heated at 70°C for 10 minutes and loaded
onto a NuPAGE 10% Bis-Tris gel (1.5 mm, 15 wells;
Invitrogen, Carlsbad, CA, USA). The molecular weight
marker used was a Bio-Rad kaleidoscope prestained
standard (Bio-Rad, Hercules, CA, USA). Run conditions
were 150 V for 1 hour at room temperature (RT). Using
a semidry transfer apparatus (Bio-Rad), proteins were
transferred onto a nitrocellulose membrane. Primary
antibody diluted at 1:1,000 in 5% milk for pSTAT3
pY705 (Cell Signaling Technology) and total STAT3
(Cell Signaling Technology) diluted to 1:1,000 in 5%
bovine serum albumin (BSA) in Tris-buffered saline
(TBS) were incubated overnight at 4°C with 5% milk in
TBS plus 0.05% Tween 20 (TBS-T). Anti-rabbit immu-
noglobulin G (IgG), horseradish peroxidase (HRP)-
linked secondary antibody was used at 1:2,000 dilution
(Cell Signaling Technology). Detection was performed
using SuperSignal West PicoC h e m i l u m i n e s c e n tS u b -
strate (Pierce Biotechnology, Rockford, IL, USA). Densi-
tometry was performed using Gel-Pro Analyzer 3.1
software (Media Cybernetics, Inc., Bethesda, MD, USA).
Enzyme assays
The kinase activity of baculovirus-expressed human JAK
kinases (JAK1, JAK2, JAK3 or TYK2) was measured
using the time-resolved fluorescence detection system as
described elsewhere [17]. Each 96-well Costar high bind-
ing plate (Corning, Corning, NY, USA) was coated with
100 μl/well of 10 μg/ml neutravidin (Pierce Biotechnol-
ogy) in TBS at 37°C for 2 hours, followed by 100 μl/well
of 1 μg/ml 15-mer peptide substrate (biotinyl-amino-
hexanoyl-EQEDEPEGDYFEWLE-amide; Infinity Biotech
Research and Resource, Aston, PA, USA) at 37°C for 1
hour. The kinase assay mixture (total volume 100 μl/
well), consisting of 20 mM 4-(2-hydroxyethyl)-1-pipera-
zineethanesulfonic acid (pH 7.2), adenosine triphosphate
(ATP) (Km level for each kinase), 1 mM MnCl2,0 . 1 %
BSA, and test compound (diluted in DMSO; 2.5%
DMSO final concentration in assay), was added to the
assay plate. The concentrations of ATP used were as
follows: 0.2 μM ATP for JAK1, JAK2, and TYK2 and 0.1
μM ATP for JAK3. Enzyme was added, and the reaction
was allowed to proceed for 20 minutes at RT. Detection
of the phosphorylated product was performed by adding
100 μl/well of Eu-N1-labeled PY100 antibody (PerkinEl-
mer Life Sciences, Boston, MA, USA) diluted 1:5,000 or
1:10,000 in 0.25% BSA in TBS-T. Samples were incu-
bated at RT for 1 hour, followed by the addition of 100
μl of enhancement solution (PerkinElmer Life Sciences).
Plates were agitated for 10 minutes, and the fluores-
cence of the resulting solution was measured using the
PerkinElmer EnVision 2102 or 2104 multilabel plate
reader. Half maximal inhibitory concentration (IC50)
values were determined using the four-parameter logis-
tic model in XLFit 4 (IDBS, Ltd., Guildford, UK).
CAIA model
Acclimated mice were randomized, prebled and mea-
sured for baseline inflammation before any studies were
initiated. On day 0, DBA/1 female mice were injected
intravenously (i.v.) with 100 μl of a saline solution con-
taining 1.5 mg of a 10 mg/ml cocktail of arthritogenic
monoclonal antibodies directed against different epi-
topes of CII (Chondrex, Redmond, WA, USA) sus-
pended in saline solution. On day 3, mice were injected
intraperitoneally (i.p.) with 100 μlo f5 0μgo fEscheri-
chia coli 0111:B4 lipopolysaccharide (LPS) (0.5 mg/ml
stock) (Chondrex) and fed gel food during recovery.
Two days after LPS treatment monitoring of arthritic
paws began. Peak arthritis usually occurred 2 to 3 days
following LPS treatment. To ensure that enough mice
were available for each study, a surplus of animals were
induced, and only those mice that met the criteria were
entered into the study. Mice that exhibited a clinical
score greater than 1 in each limb were considered
arthritic and were entered into the study. If mice did
not meet the study criteria, they we excluded and killed.
Mice were then randomized and ear-tagged for identifi-
cation. Study group sizes were determined after study
entry, but consisted of at least 10 mice per group.
Arthritis clinical score tables can be found elsewhere
[18]. Briefly, a score of 0 denotes no evidence of
erythema and swelling, 1 denotes erythema and mild
swelling confined to the tarsus, 2 denotes erythema and
mild swelling extending from the ankle to the midfoot,
3 denotes erythema and moderate swelling extending
from the ankle to the metatarsal joints, and 4 denotes
erythema and severe swelling encompassing the ankle,
foot and digits. The black arrows in the respective fig-
ures indicate treatment start. CEP-33779 compound was
administered orally (p.o.) by gavage instrument sus-
pended in vehicle twice daily (b.i.d.). Vehicle consisted
of PEG400 plus 1% DMSO administered p.o., b.i.d., and
dexamethasone (Dex) (Hanna’s Pharmaceutical Supply,
Wilmington, DE, USA) at 1.5 mg/kg was administered i.
p. three times weekly in saline solution and continued
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experiment. Mice were cheek-bled for serum sample
collection for cytokines and antibodies throughout the
experiment. All samples were kept at -80°C until ready
to assay. At about 4 weeks, mice were harvested for
spleen, serum and arthritic paws for STAT and cytokine
quantitation and histological analysis. For earlier valida-
tion, studies were ended around 3 to 4 weeks after
induction, and the paws were removed at various time
points to measure cytokine levels over time.
CIA model
Acclimated mice were randomized, prebled and mea-
sured for baseline inflammation before any studies were
initiated. On day 0, DBA/1 female mice were given a
primary immunization with equal volumes of bovine
CII, 2 mg/ml stock in 0.05 M acetic acid (Chrondrex)
suspended in 5 mg/ml Complete Freund’sA d j u v a n t
(CFA) (Chondrex) emulsion, yielding an injection of 100
μg of CII at 100 μl into the base of the tail intradermally
(i.d.). At day 21 post-primary immunization, mice were
rechallenged with CII emulsified in Incomplete Freund’s
Adjuvant (IFA) (Thermo Scientific, Rockford, IL, USA)
subcutaneously (s.c.) on the flank of the mouse. On day
28, each mouse received an i.p. injection of E. coli 0111:
B4 LPS (0.5 mg/ml stock) (Chondrex) at 10 μg in 100 μl
of saline solution (25 to 50 μg of LPS reduced to 10 μg
per mouse to reduce mortality associated with endotoxic
shock). Around day 35 the mice begin to show signs of
paw inflammation and disease. Before the start of treat-
ment, mice were randomized, grouped, scored, ear-
tagged and prebled to determine baseline disease. To
ensure that enough mice were included in each study, a
surplus of animals were induced, and only those mice
that met the study criteria were entered into the study.
Mice that exhibited a clinical score greater than 1 in
each limb were considered arthritic and were entered
into the study. If mice did not meet the study criteria,
they were excluded and killed. Mice were then rando-
mized and ear-tagged for identification. Study group
sizes were determined after study entry, but consisted of
at least 10 mice per group. Arthritis clinical scores were
the same as those used to score the mice in the CAIA
model (see CAIA model). The black arrows in the
respective figures indicate treatment start. CEP-33779
compound was administered orally by gavage suspended
in vehicle b.i.d. Vehicle consisted of PEG400 plus 1%
DMSO p.o., b.i.d., and 1.5 mg/kg Dex (Hanna’s Pharma-
ceutical Supply) was administered i.p. three times weekly
in saline solution and continued from the peak of
inflammation until the endo ft h ee x p e r i m e n t .M i c e
were cheek-bled for serum sample collection for cyto-
kines and antibodies throughout the experiment. All
samples were kept at -80°C until ready to assay. At
about day 60, mice were harvested for spleen, plasma
and arthritic paws for STAT and cytokine quantitation
and histological analysis.
APM for carrageenan-induced inflammation
Details on the establishment and design of this rapid
inflammation screening model can be found elsewhere
[19,20]. Briefly, Balb/c mice were injected s.c. with 4 ml
of sterile air on day -5, baseline measurements were
recorded, and mice were randomized into groups. Mice
entered the study upon air pouch maintenance by day
-3, when 2 ml of sterile air was injected for air pouch
maintenance. On day 0, mice were given a 1% carragee-
nan (Sigma) injection suspended in saline solution
directly into the air pouch. This induced a rapid inflam-
matory influx of primarily neutrophils and macrophages
(data not shown). Compound was administered in saline
solution at milligrams per kilogram concentrations in
100 μl total volume directly into the air pouch simulta-
neously with carrageenan injection (1% carrageenan in
saline solution). The response was followed by a spike
in IL-6, TNFa,a n dI L - 1 b pouch cytokines (data not
shown) and was completed by day 8 (data not shown).
Twenty-four hours after carrageenan and compound
administration, 100 μl of air pouch fluid was removed
along with cellular exudates. Cellular exudates were cen-
trifuged, the supernatants were processed for Luminex
cytokine analysis (Invitrogen), and the cell pellets were
counted for total live and dead cells. Total cell counts
were performed using BD TruCount beads (BD Bios-
ciences, San Jose, CA, USA), and cellular analysis was
performed using 7-aminoactinomycin D (Sigma) as a
viability dye to exclude dead cells. Hemoglobin content
was determined using the Drabkin’s assay (Sigma).
Histology
CAIA and CIA arthritis models
At the end of each experiment, front and hind paws
(including carpus and tarsus) were removed from the
body of each animal for histological analysis. Skin from
the ends of the digits was removed, and the metatarsal
region skin was perforated using surgical scissors to
allow full decalcification. Samples were treated using a
decalcification procedure with formic acid as described
elsewhere [21,22]. After 7 to 10 days of decalcification,
samples were washed for 2 hours in distilled water and
stored in 70% ethanol at 4°C until they were ready to be
processed. Samples were paraffin-embedded, sectioned,
and stained with hematoxylin and eosin as well as Safra-
nin O for matrix degradation (images not shown, used
by pathologist for scoring). All histological work was
performed at the Wistar Institute (Philadelphia, PA,
USA). Images were collected using an Olympus BX50
microscope equipped with an Olympus DP70 camera
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ley, PA, USA). A total of five mice from each group
were analyzed via histopathology, and representative ×
10 original magnification images are shown for each
group tested.
Measurement of serum anti-collagen type I and anti-CII
autoantibodies
Serum was collected every 1 to 2 weeks and stored at -80°
C until use. Thawed samples were analyzed by using an
in-house-generated CII and collagen type I (CI) enzyme-
linked immunosorbent assay (ELISA) method. Briefly,
each well of a 96-well plate was coated with 50 μlo f5
μg/ml CI (Chondrex) or CII (Chondrex) in borate-buf-
fered saline (BBS) (0.025 M Na2B4O7-10H2O, 0.01 M
H3BO3, and 0.075 M NaCl; pH 8.4) buffer overnight at 4°
C. Plates were washed with BBS plus 0.1% Tween 20
three times before proceeding. Standard curves were gen-
erated using purified mouse anti-CI or anti-CII antibody,
and serum was added at 50 μl per well and then incu-
bated at RT for 1 hour followed by being washed with
BBS plus Tween 20. After being washed, 50 μlo f1μg/ml
rabbit anti-mouse HRP-fragment antigen-binding anti-
body was added as a detection antibody (Rockland Biolo-
gicals, Gilbertsville, PA, USA) and incubated at RT for 45
minutes. Plates were washed four times with BBS plus
Tween 20, then 100 μl of tetramethylbenzidine substrate
was added and the reaction was stopped using 100 μlo f1
MH 2SO4. The plates were read at 450 nm with a refer-
ence wavelength of 570 nm.
ELISPOT assays
Descriptions of T-cell and B-cell ELISPOT methods can
be found elsewhere [23,24]. The technique used for each
is described briefly here.
T-cell ELISPOT assays
For CIA experiments, Millipore nitrocellulose IP filter
plates (Millipore, Billerica, MA, USA) were coated with
either anti-mouse IFNg (AN18; MabTech, Mariemont,
OH, USA) or anti-mouse IL-4 (11B11; eBioscience, San
D i e g o ,C A ,U S A )a t7μg/ml or 2 μg/ml, respectively, in
sterile phosphate-buffered saline (PBS) at 60 μl/well and
incubated for 3 hours at RT or overnight at 4°C. Coated
wells were washed with PBS plus 0.1% Tween 20 and
patted semidry before blocking using complete media for
at least 1 hour before use. Purified mouse CII (Chron-
drex), CI (Chrondrex), or third-party control chicken oval-
bumin (OVA) (Sigma) was used to challenge 1 million
processed splenocytes per well at 10 μg/ml total antigen
concentration. Media alone was used as a background
control, OVA was used as a third-party control, and phor-
bol 12-myristate 13-acetate plus ionomycin was used as a
positive control for IFNg and IL-4 release by T helper 1
(Th1) and Th2 cells, respectively.
B-cell ELISPOT assays
B-cell ELISPOT components were obtained from Mab-
Tech, and nitrocellulose IP filter plates were obtained
from Millipore. Briefly, for CIA experiments, B-cell ELI-
SPOT wells were activated using ethanol, then washed
and coated with 10 μg/ml purified bovine CII or purified
bovine CI (Chrondrex) in sterile PBS. OVA was used as
a third-party control, and media alone was used for
background. Processed splenocytes were added to each
well and were not stimulated with LPS to avoid true ex
vivo frequencies of antibody-secreting cell types (ASCs).
Anti-mouse total IgG was used as a positive control for
total IgG-producing ASCs and was used to normalize
results. Cell frequencies for the detection of each anti-
gen were previously identified during optimization and
validation phases for each model tested (data not
shown). A total of 500,000 cells were added to each well
for the CI- and CII-coated wells for CIA experiments.
B-cell ELISPOT spots were incubated overnight at 37°C
and 5% CO2. To develop each assay, a secondary anti-
body (MabTech) was added to each well, incubated, and
washed; alkaline phosphatase streptavidin was used as a
conjugate (Jackson Immunoresearch, West Grove, PA,
USA); and 5-bromo-4-chloro-3’-indolylphospate r-tolui-
dine salt (BCIP) and nitro-blue tetrazolium chloride
(NBT) (Rockland Biologicals) was used as a substrate
and developed until spots were visible. All ELISPOT
analyses were performed using a CTL ImmunoSpot
Analyzer and CTL BioSpot software (Cellular Technol-
ogy Ltd., Shaker Heights, OH, USA).
Measurement of serum cytokines via multiplex Luminex
bead assays
Frozen plasma at -80°C was thawed on ice, vortexed,
and then centrifuged for 10 minutes to remove debris
and aggregates. A total of 25 to 50 μlo fs e r u mw e r e
used for Luminex assays (Invitrogen) following the man-
ufacturer’s instruction. Ten different mouse cytokines
were measured using the mouse cytokine 10-plex bead
kit (Invitrogen). Briefly, filter plates (Millipore) were pre-
wetted with 200 μl of wash solution (kit component),
and 25 μl of beads were added per well. Serum samples
were diluted, and a total volume of 50 μl/well was
added (that is, 25 μl of sample serum plus 25 μl of assay
diluent). Plates with beads were incubated for 2 hours at
RT on an orbital shaker in the dark. At the end of the
incubation, the plates were washed twice in buffer and
100 μl of secondary biotinylated antibody were added at
a 1:10 dilution in biotin diluent provided with the kit.
Plates were incubated at RT for 1 hour in the dark, then
washed twice in buffer. Streptavidin in assay diluent was
a d d e da t1 0 0μl/well, then incubated for 30 minutes at
RT in the dark. Plates were washed three times with
100 μl of wash solution and agitated for 2 to 3 minutes
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Luminex xMAP 200 unit with data acquisition and ana-
lysis software (Invitrogen). All bead washing was per-
formed using a vacuum manifold unit (Pall, Port
Washington, NY, USA).
Measurement of paw cytokines and pSTAT levels via
multiplex Luminex bead assays
The method described in this subsection has been pub-
lished elsewhere [25]. Briefly, the front (including car-
pus) and back (including tarsus) right paws were
collected, frozen in dry ice-cooled isopentane, and
stored at -80°C until use. The paws were cut to 2 mm ×
2 mm segments and kept on dry ice in round-bottomed
polypropylene tubes. Seven hundred microliters of tissue
extraction buffer containing protease inhibitor cocktail
(Calbiochem, San Diego, CA, USA) and Halt phospha-
tase inhibitor cocktail (Thermo Scientific) or Roche
phosphatase inhibitor cocktail (Roche, Indianapolis, IN,
USA) in tissue extraction reagent I (Invitrogen) were
added to each sample. Samples were homogenized fro-
zen using a PT 10/-35 Polytron Homogenizer (Brink-
mann, Dallas, TX, USA). After homogenization, samples
were centrifuged at 4°C and 2,000 × g for 10 minutes,
and the supernatants were recentrifuged at 4°C at maxi-
mum speed, 14,000 × g, for 15 minutes. Supernatants
were carefully removed to avoid picking up the top layer
of lipids/adipose debris. The protein concentration was
measured using a bicinchoninic acid protein assay
(Pierce Biotechnology) and adjusted to 3 mg/ml. A
minimum of 25 μl of this extraction was used in the
above-described protocol using the mouse cytokine 10-
plex bead kit (Invitrogen) or STAT1, 3, 5a/b Phospho 3-
Plex Panel (Invitrogen).
Compound quantification (Pharmacokinetics)
Plasma and protein extracted from paw and spleen sam-
ples were submitted for quantitative analysis to deter-
mine the respective compound concentrations. Blood
samples were collected into heparinized tubes and placed
on wet ice until being centrifuged (16,000 × g for 5 min-
utes) to separate the plasma. Supernatant was collected
and stored at -20°C pending analysis. At the time of ana-
lysis, two volumes of cold acetonitrile containing an
internal standard (alprenolol) were added to each sample,
which were then vortexed and centrifuged. The superna-
tants were removed and placed into an autosampler vial,
and the amount of compound present in the samples was
analyzed by liquid chromatography/mass spectrometry.
The concentration of compound in the samples was
quantified against a mouse plasma standard curve made
via serial dilution in a concentration range from 5 to
20,000 ng/ml. Samples containing concentrations more
than 10% above the top of the standard curve were
diluted 1:10 with acetonitrile. The limits of detection for
plasma, paw, and spleen were <10 ng/ml.
Statistical analysis
All ELISA or Luminex assays were analyzed using linear
regression curves to determine the concentration of ana-
lyte following data acquisition. Mann-Whitney nonpara-
metric one- or two-way analysis of variance (ANOVA)
was used as for statistical testing as noted in the figure
legends, depending on the experiment and the tested
hypothesis. Bonferroni posttests were used to compare
replicates in ANOVA tests. A P value < 0.05 was con-
sidered significant. For all studies, a minimum of 10
mice were included in each experimental group. The
statistical software used was GraphPad Prism version
5.01 (GraphPad, La Jolla, CA, USA), and calculations
were performed using Microsoft Excel software (Micro-
soft Corp., Redmond, WA, USA).
Results
In vitro and in vivo characterization of the JAK2 inhibitory
activity of CEP-33779
CEP-33779 was synthesized and identified as a potent
inhibitor of the target kinase in an assay of the isolated
human enzyme (IC50 = 1.8 ± 0.6 nM) (Figure 1A).
When evaluated against the other members of the JAK
family, CEP-33779 demonstrated varying degrees of
selectivity from >40-fold versus JAK1 to >800-fold
against TYK2 (Figure 1A). The broad selectivity of CEP-
33779 with respect to inhibition of other members of
the kinome was assessed using binding assays for a
panel of 402 kinases [26]. At a test concentration of 1
μM, CEP-33779 was highly selective, with 9% of the
panel inhibited by >90% and only 1% inhibited by >99%
(S(90)402 = 0.09 and S(99)402 = 0.01, respectively), using
the selectivity score defined by Karaman et al. [27] (see
also Figure 1A). In a cellular system, CEP-33779 was
shown to inhibit JAK2 in irf-bla TF-1 cells utilizing the
GeneBLAzer reporter assay (Invitrogen) (data not
shown) and in HEL92 cells by measuring the phosphor-
ylation of STAT5 (Figure 1B). Activity against pSTAT3
was also observed (data not shown); however, STAT3
can be activated via both the epidermal growth factor
receptor (EGFR) and Src kinase signaling pathways
[28,29]. The lack of activity against either of these
kinases in the profiling panel suggests that the effects
on pSTAT3 were mediated by inhibition of JAK2. The
activity of CEP-33779 was also demonstrated in an in
vivo PD assay using HEL92 cells (Figure 1C). The in
vitro and in vivo profiles of CEP-33779 were consistent
with its identification as a potent and selective inhibitor
of JAK2.
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Page 6 of 15JAK2 inhibition suppresses CAIA and inhibits local
cytokine responses
Anti-CII antibody was delivered to mice i.v., and oral
administration of compound was initiated upon indivi-
dual mice meeting minimum score requirements and
being entered into dosage groups. CEP-33779 was admi-
nistered at 10, 30, or 55 mg/kg p.o., b.i.d., for a total of 2
weeks. Vehicle groups were treated with PEG400 in 1%
DMSO. Dex was used as a glucocorticoid standard of
care reference and was given i.p. in saline solution alone
three times weekly (every 48 hours) at 1.5 mg/kg total
body mass. This high dose of Dex, which was chosen to
define a fully treated disease index, is within the range
(0.3 to 1.5 mg/kg) employed by several groups who have
used inflammation models [30-32]. Individual paws were
scored and measured using a standard electric caliper,
and the measurements were averaged to produce the
graphed results. Dose-dependent responses were evident
by the reduction in mean paw thickness or size over time
w i t ht r e a t m e n t( 1 . 3 - f o l dd r o pa td a y1 3f o r5 5m g / k g
dose compared to vehicle) (Figure 2A, top). This corre-
lated well with a decrease in total clinical score peaking
at the highest dose used, 55 mg/kg (2.4-fold reduction at
day 13 for 55 mg/kg dose compared to vehicle) (Figure
2A, bottom). The efficacy observed at the 55 mg/kg dose
of CEP-33779 paralleled that observed with Dex (for days
13 to 20) (Figure 2A). For all animals treated, total body
mass was not significantly different from that of vehicle-
treated animals (Additional file 1). In previous experi-
ments, nondiseased animals showed similar weight gain
compared to their vehicle-treated counterparts (data not
shown). Analysis of CEP-33779 in plasma, paw, and
spleen at 2 and 6 hours after oral administration on day
20 demonstrated dose-related increases in the levels of
compound (Figure 2B). While compound levels in the
target tissue, the paw, were relatively low, they were rela-
tively constant between the two time points (average
659.0 ng/g at 2 hours for 55 mg/kg versus 472.0 ng/g at 6
hours for 55 mg/kg) (Figure 2C).
To investigate the effect of CEP-33779 on levels of
pSTAT and cytokines in the paws of treated mice, a
method was developed whereby synovial fluid and cellu-
lar joint extracts could be obtained from the paws and
ankles of diseased animals for analysis using multiplex
bead arrays [25]. On the basis of the activity of CEP-
33779 as a JAK2 inhibitor, pSTAT5, pSTAT3, and pos-
sibly pSTAT1 were hypothesized to be reduced in the
paws of treated mice as previously suggested on the
basis of in vitro and in vivo experiments (Figures 1A
and 1B and data not shown). Using multiplex bead kits,
it was determined that measurement of pSTAT was
similar and more quantitative than using Western blot
analysis alone. Consequently, multiplex analysis was
used as the primary method of measuring pSTAT for all
further studies reported here [25].
Local paw pSTAT5 levels in diseased animals were
similar to those in mice treated with vehicle alone ([25]
and data not shown). However, pSTAT3 dominated as
the most highly upregulated STAT molecule in diseased
compared to nondiseased animals and was significantly
reduced in total concentration upon JAK2 inhibition
(Figure 3A and data not shown). pSTAT1 was barely
detectable in all samples tested (data not shown).
pSTAT3 levels were nearly abolished in the paw 2 hours
after CEP-33779 treatment (Figure 3A, left) and only
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B.
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Figure 1 Biochemical and cellular characterization of a
selective Janus kinase 2 (JAK2) inhibitor, CEP-33779. (A)
Enzymatic inhibitory activities of CEP-33779 against JAK2 and family
members. Inhibition of the kinase activity of each recombinant
enzyme (JAK2 and JAK3) by CEP-33779 was evaluated using a plate-
based, time-resolved fluorescence detection system. The effect in a
cellular system was measured using irf-bla TF-1 cells (JAK2) and Ba/
F3 JAK3 cells not tested for JAK1 and TYK2. Half maximal inhibitory
concentration (IC50) values are reported as the averages ± SD of at
least four independent determinations. FAK, focal adhesion kinase.
(B) In vitro activity of CEP-33779 in HEL92 cells and potent JAK2
inhibition as determined by the inhibition of phosphorylation of
downstream target signal transducer and activator of transcription 5
(pSTAT5), vehicle (veh). HEL92 cells were treated with increasing
concentrations of CEP-33779 as indicated for 1 hour in serum-free
media. Extracts were prepared in a Triton X-100-based lysis buffer,
protein concentrations were determined, and equal amounts were
resolved on sodium dodecyl sulfate polyacrylamide electrophoresis
(SDS-PAGE) gels and blotted. STAT5 and pSTAT5 were analyzed
using specific antibodies (see Materials and methods). Blots were
scanned, and signals for each group were determined using GelPro
as phosphor/total. Prism software was used to calculate the IC50
values. (C) In vivo pharmacodynamic (PD) in which mice were
dosed orally (p.o.) with 55 mg/kg CEP-33779 before the removal of
HEL92 tumor extracts (2 hours postinjection) and quantitation of
STAT5 and pSTAT5 levels using Western blot analysis. Each lane
represents an individual sample. Profiling studies for CEP-33779
were repeated for HEL92 cells and performed in several tumor lines
both in vitro and in vivo, reconfirming JAK2 inhibition (data not
shown).
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Page 7 of 15slowly began to recover at 6 hours after CEP-33779
treatment (Figure 3A, right). The expression of total
paw pSTAT3 decreased during the course of disease
when treated with CEP-33779 as compared to vehicle
control mice (Figure 3B). Levels of pSTAT3 were ele-
vated in CAIA mice because of the requirement to
p r i m em i c ew i t h2 5μgo fL P So nd a y3a f t e ra n t i b o d y
transfer; however, disease maintenance was evident in
the sustained paw inflammation and pSTAT3 activity
over time in these animals (Figure 3B). Within 24 hours
after CEP-33779 b.i.d. treatment, the reduction in
pSTAT3 level was significantly greater than that of Dex
as compared to vehicle alone (Figure 3B, days 6 and 7;
P <0 . 0 1f o r3 0m g / k ga n dP < 0.001 for 55 mg/kg as
compared to vehicle). This reduction of pSTAT3 was
reached by Dex treatment 48 hours after treatment
initiation (Figure 3B, days 6-8). CEP-33779 reduced
pSTAT3 expression to the lower limits of the assay
throughout the remainder of the studies (Figure 3B).
Reduced paw swelling accompanied by a reduction in
pSTAT3 expression strongly suggested that, at these
levels, a decrease in the expression of several cytokines
controlled by STAT3 should be observed. In a repeat of
the previous experiment using the 55 mg/kg and 100
mg/kg doses, paw extracts were analyzed for the expres-
sion level of several proinflammatory cytokines. Both
doses of CEP-33779 significantly reduced the level of
several of the cytokines implicated in the pathogenesis
of RA (for example, IL-1b,T N F a,a n dI L - 6 )( F i g u r e3 C
and Additional file 2, Figure S2C) [33]. Dose-dependent
reductions were observed for all cytokines tested in paw
extracts, especially for IL-12, IL-2, GM-CSF and IL-4
(Figure 3C, P < 0.01 compared to vehicle; Additional file
2, Figure S2A). For several of these cytokines, CEP-
33779 significantly decreased cytokine expression below
that of high-dose Dex alone (Figure 3C, P <0 . 0 5c o m -
pared to vehicle), and the 100 mg/kg dose lowered and
sustained cytokine suppression for the remainder of the
study (Figure 3C, IL-1b,I L - 6 ,T N F a, IL-12; P <0 . 0 1
compared to vehicle). Histological analyses of decalcified
front and hind limbs showed that treatment with CEP-
33779 reduced several clinical features associated with
progressive RA (Figure 3D). Independent pathologist
scoring and image collection allowed us to determine
that treatment with CEP-33779 could significantly
decrease several parameters, including matrix erosion,
subchondral osteolysis, osteoproliferation, synovial pro-
liferation, pannus formation, and degree of inflamma-
tion, as compared to vehicle controls (Table 1). Dose-
dependent responses upon JAK2 inhibitor treatment
resulted in reduced bone degradation, reduced tissue
destruction, and reduced osteoarthritis as evidenced by
the histopathology images (Figure 3D).
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Figure 2 JAK2 blockade ameliorates collagen antibody-induced
arthritis (CAIA) paw inflammation. Female DBA/1 mice were
injected intravenously (i.v.) with purified anti-collagen type II (anti-
CII) antibodies, and then 25 μg of lipopolysaccharide (LPS) was
administered intraperitoneally (i.p.) 3 days later to induce arthritis by
day 5. Mice that met the arthritis criteria score of 1 per paw were
entered into the study. CEP-33779 was administered p.o. twice daily
(b.i.d.) throughout the experiment, 1.5 mg/kg dexamethasone (Dex)
was administered i.p. three times weekly and vehicle (PEG400 + 1%
dimethyl sulfoxide (DMSO)) was administered p.o. (A) Mean paw
size (individual paws measured for thickness) measured over time
(top) and total clinical score from each paw were recorded
(bottom). *P < 0.05; black star, P < 0.01; #P < 0.001. Statistical
significance was measured by using two-way analysis of variance
(ANOVA), n ≥ 10 mice per group. (B) Pharmacokinetics (PK) of CEP-
33779 at 55 mg/kg, 30 mg/kg and 10 mg/kg, p.o., once daily (s.i.d.),
in the plasma, paw and spleen of treated mice, with statistical
significance not determined; n = 4 mice per group tested. All
graphs show means ± SEM. Study size shows n ≥ 10 mice per
group and n ≥ 5 mice for individual assays. Black arrows in parts A
and B indicate treatment start.
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Figure 3 Disease treatment reflected in local paw environment supports the use of a selective JAK2 inhibitor for suppressing joint
inflammation. DBA/1 female mice were injected i.v. with purified anti-CII antibodies, then administered 25 μg of LPS i.p. 3 days later to induce
arthritis by day 5. Mice that met the arthritis criteria score of 1 per paw were entered into the study. CEP-33779 was administered p.o., b.i.d.,
throughout the experiment, Dex was administered at 1.5 mg/kg three times weekly i.p., and vehicle (PEG400 + 1% DMSO) was administered p.o.
(A) Spleen and paw phospho-STAT3 concentrations were determined by using Luminex bead kits, with the concentrations shown along the y-
axis in units per milliliter per 3 mg of total protein as determined by using a bovine serum albumin (BSA) assays. Tissues were removed 2 and 6
hours after administration of CEP-33779 p.o. at 55 mg/kg. Graph shows means ± SEM. *P < 0.05 by two-way ANOVA. (B) Paw phospho-STAT3
expression in CAIA mice over time with CEP-33779 treatment b.i.d. as measured using a Luminex kit. Black arrow indicates treatment start. (C)
Paw cytokines were measured as described elsewhere [25]. Mouse 10-plex Luminex kits were used to measure paw cytokines. Cytokines shown
include interleukin (IL)-12, interferon g (IFNg), IL-2, IL-1b, tumor necrosis factor a (TNFa) and granulocyte macrophage colony-stimulating factor
(GM-CSF). Black arrows indicate treatment start. (D) Hematoxylin and eosin-stained, paraffin wax-embedded sections from treated mice show
infiltrates and damaged joints. Representative (pathologist-selected) images are shown at × 10 original magnification. Tissues were also stained
with Safranin O for matrix degeneration (data not shown). Tissues from five representative mice from each group were sent for histological
analysis and graded according to an accepted scoring method (see Materials and methods). All graphs show means ± SEM, and all statistics
were calculated using Prism software and two-way ANOVA analysis. *P < 0.05. **P < 0.01. ***P < 0.001. Study size shows n ≥ 10 mice per group
and n ≥ 5 mice for individual assays.
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reduces the generation of disease-promoting Th1 cells
To test JAK2 inhibitors in a more physiologic and pro-
gressive disease model of RA (that is, the CIA model),
arthritic mice that previously had been sensitized against
self-CII and exhibited the phenotype of natural RA were
treated with CEP-33779. Laboratory studies demon-
strated that this CIA model exhibited arthritic flares as
previously reported in the literature (data not shown)
[18]. Early model optimization studies consistently gen-
erated robust CIA phenotypes that were absent from
control-treated, nondiseased animals (data not shown).
CIA animals were treated with CEP-33779 at 30, 55,
and 100 mg/kg doses b.i.d, p.o. Vehicle and the stan-
dard-of-care reference drug, Dex, at 1.5 mg/kg, were
administered as described above. There was a clear
reduction in the mean paw size (individual values for
paws collected but not shown), along with a reduction
in clinical score, in a dose-dependent manner observed
in treated mice (Figure 4A, top and bottom). The most
striking observation was the nearly identical suppression
of paw swelling in mice treated with 100 mg/kg CEP-
33779 versus those treated with high-dose Dex (Figure
4A, red and violet lines). Also, at least with regard to
the objective parameter of mean paw size, there was a
drop in the swelling of the 100 mg/kg treated group
preceding that of the Dex-treated group (Figure 4A).
Again, differences in the mechanism of action may
account for this result. As expected, pSTAT3 was also
significantly reduced in mice treated with CEP-33779 at
55 mg/kg (Figure 4B, P < 0.01) and 100 mg/kg (Figure
4B, P < 0.001). For all three CEP-33779 doses, reduc-
tions in local paw pSTAT3 expression directly corre-
sponded to decreases in several serum and paw
cytokines involved in the disease progression of arthritis
(Figure 4C, IL-12, IL-2, IL-10, and TNFa; P <0 . 0 5 )
(Additional file 2, Figure S2A; IL-4, P <0 . 0 0 1 )a n d
spleen IL-12 (Additional file 2, Figure S2B; P <0 . 0 5 ) .A
reduction in paw IL-6 (Additional file 2, Figure S2C; P <
0.05) with CEP-33779 treatment was also observed.
However, this cytokine was difficult to monitor because
of the IL-6-driven flares causing spikes in the vehicle
groups (Additional file 2, Figure S2C). Body mass did
not significantly change for any group tested; however,
mice treated with CEP-33779 appeared healthier and
retained greater body mass longer than those in the
control groups (unpublished observations, KL Stump)
(Additional file 3).
T h ed o s er e s p o n s eo fC E P - 3 3 7 7 9t r e a t m e n tw a sm o s t
clearly observed when IL-12, the main precursor and
driver of pathogenic Th1 and Th17 cells [34,35], was
measured (Figure 4C). High-dose Dex was effective in
suppressing endogenous IL-12 expression in the sera of
arthritic mice, but all three doses of CEP-33779 were
able to significantly decrease the level of IL-12 com-
p a r e dt ot h a to b s e r v e dw i t hD e x( F i g u r e4 C ) .S i n c eI L -
12 is the differentiating cytokine for Th1 cells (via T-bet
expression) and anti-CII Th1 cells are the main drivers
of paw inflammation in the CIA model, it was hypothe-
sized that if CEP-33779 can suppress circulating IL-12,
then the total frequency of CII-specific T cells should be
reduced upon treatment. With the knowledge that the
same Th1 cells found locally in the paw must have cir-
culated throughout the animal and entered secondary
lymphoid organs, whole splenocytes from treated CIA
mice were restimulated with the purified CII fragment
(CB11) containing immunodominant epitopes ex vivo in
IFNg T-cell ELISPOT assays. As expected, there was a
significant reduction in the frequency of CB11-specific,
IFNg-secreting T cells when treated with either Dex or
CEP-33779 at 55 mg/kg or 100 mg/kg b.i.d, p.o., for 4
weeks (Figure 4D; P < 0.001). Representative ELISPOT
images demonstrate that higher doses of CEP-33779
result in a greater reduction in the frequency of Th1-
Table 1 CAIA model joint inflammation histopathology scores
a
Group Proteoglycan
loss
Matrix
erosion
Subchondral
osteolysis
Osteoproliferation Synovial
proliferation
Pannus
formation
Inflammation
degree
Vehicle 1.55 ± 0.07 3.12 ± 0.71 2.50 ± 1.00 1.65 ± 0.47 2.00 ± 0.81 1.12 ± 0.85 1.75 ± 0.95
CEP-33779 10
mg/kg
1.39 ± 0.38 3.40 ± 2.07 2.30 ± 1.30 1.70 ± 1.09 2.40 ± 1.34 1.30 ± 0.97 1.60 ± 1.14
CEP-33779 30
mg/kg
1.12 ± 0.88 0.75 ± 0.95 0.62 ± 0.47* 0.87 ± 0.62 0.25 ± 0.50* 0.00 ± 0.00 0.12 ± 0.25*
CEP-33779 55
mg/kg
2.05 ± 0.07 0.70 ± 0.44* 0.60 ± 0.41** 0.30 ± 0.72* 0.30 ± 0.44* 0.00 ± 0.00* 0.20 ± 0.27*
Dex 1.5 mg/kg 0.98 ± 0.44 1.00 ± 0.79 0.50 ± 0.35** 0.70 ± 0.44 0.40 ± 0.54* 0.10 ± 0.22 0.30 ± 0.44*
Compared to
vehicle
*P < 0.05 **P < 0.01 ***P < 0.001
aCAIA, collagen-antibody induced arthritis; Dex, dexamethasone. Hematoxylin and eosin- and Safranin O-stained, paraffin wax-embedded carpus and tarsus
sections were scored by a board-certified independent pathologist for the criteria described in Materials and methods. Values are means ± SD for the tarsus only.
P values show significance as compared to vehicle group; n = 5 mice per group. Statistical test used was two-way analysis of variance (ANOVA). *P < 0.05. **P <
0.01. ***P < 0.001.
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Figure 4 JAK2 blockade reduces several disease correlates in a model of chronic degenerative arthritis.F e m a l eD B A / 1m i c ew e r e
injected with purified CII in Complete Freund’s Adjuvant (CFA) i.d., then boosted with CII in Incomplete Freund’s Adjuvant (IFA) s.c. on day 21
followed by a day 28 LPS injection i.p. to induce collagen-induced arthritis (CIA). Mice that scored 1 or better for each paw were considered
arthritic and entered into the study. Treatments started after 7 to 10 days of full arthritis. CEP-33779 was administered p.o., b.i.d., throughout the
remainder of the experiment. Dex was administered i.p. at 1.5 mg/kg three times weekly, and vehicle was PEG400 + 1% DMSO p.o., b.i.d. (A)
Mean paw size (individual paws measured) and clinical scores for each mouse are graphed. (B) Phospho-STAT3 expression in the paws of
treated CIA mice. (C) Serum cytokines (IL-12, IL-2, IL-10 and TNFa) from treated CIA mice. (D) Representative ELISPOT images showing IFNg
enzyme-linked immunosorbent spot (ELISPOT) assay results from stimulated splenocytes from treated mice challenged with CII fragment (CB11),
chicken ovalbumin (OVA) or media alone. Graph was constructed using data from five mice tested from each group. Spots were counted using
a CTL ImmunoSpot ELISPOT scanner and spot-counting software. (E) Hematoxylin and eosin-stained, paraffin wax-embedded sections from
treated CIA mice showing joint infiltrates and bone resorption. Representative (pathologist-selected) images are shown at × 10 original
magnification. Safranin O-stain sections are not shown but were used for scoring. All graphs show means ± SEM, and all statistics were
calculated using Prism software and two-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001. Study size shows n ≥ 10 mice per group and n ≥ 5
mice for individual assays. Black arrows in parts A and C indicate treatment start.
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Page 11 of 15like cell responses (Figure 4D). However, a reduction in
anti-CII IgG serum titers in CEP-33779-treated mice
was not observed (Additional file 4), suggesting that the
root of the problem, autoreactive B cells, still has to be
addressed [36]. Anti-CII antibodies were not present in
nonarthritic mice, and anti-CI antibodies were tested
but never found in this experiment or in the CIA model
(data not shown). Disease treatment using CEP-33779
led to less paw inflammation and bone deterioration as
demonstrated by histological analysis (Figure 4E) and
independent, blinded pathologist scores (Table 2). In the
CIA model, the tarsus tends to become more inflamed
than the carpus, and the opposite is observed in the
CAIA model (unpublished data, KL Stump). Both 100
mg/kg and 55 mg/kg CEP-33779 doses provided protec-
tion in the tarsus, but 100 mg/kg CEP-33779 provided
the best protection for both regions (Figure 4E). How-
ever, significance was observed only for the degree of
inflammation in the CIA model for both the 100 mg/kg
and 55 mg/kg CEP-33779 doses (Table 2) (P <0 . 0 1f o r
100 mg/kg and P < 0.05 for 55 mg/kg compared to
vehicle controls).
Inhibition of cellular immunity with JAK2 inhibition using
an air pouch inflammation model
To test the impact of CEP-33779 inhibition of JAK2 at
the cellular level, the mouse APM was utilized. Air-filled
subcutaneous pouches were maintained under sterile
conditions and injected with 1% carrageenan simulta-
neously with CEP-33779 at 10, 30, and 55 mg/kg. Saline
solution alone (vehicle) or Dex at 1.5 mg/kg was used as
the control. CEP-33779 JAK2 inhibition significantly
decreased cellular accumulation in the air pouch (Figure
5A; P < 0.05 compared to vehicle). CEP-33779 JAK2
inhibition could also inhibit the expression of IL-6 to
less than that of Dex (Figure 5B; P < 0.05 compared to
vehicle). In addition, angiogenesis was affected as mea-
sured using the indirect angiogenesis assay (Drabkin’s
assay) to measure the total hemoglobin content of the
pouch contents (Figure 5C; P <0 . 0 5c o m p a r e dt ov e h i -
cle). APM treatment with CEP-33779 provided similar
results when administered at 1 to 0.1 mg/kg (data not
shown). These data suggest that CEP-33779 inhibition
of JAK2 directly affects cellular immune function, and
thus the mechanism of action in the RA models must
be mediated at the level of leukocyte flux and cytokine
release and/or response.
Discussion
Here we report the efficacy profile of CEP-33779, a
highly selective, orally active, small-molecule inhibitor of
JAK2 that we evaluated in two mouse models of RA. PD
inhibition of JAK2 reduced mean paw edema and clini-
cal scores in both the CIA and CAIA models of arthri-
tis. Reduction in paw and serum cytokines correlated
with reduced spleen CII-specific Th1 cell frequencies as
measured by ex vivo IFNg ELISPOT assays. Both models
demonstrated histological evidence of disease ameliora-
tion upon treatment and reduced paw pSTAT3 levels.
This study demonstrates the utility of using a potent
and highly selective, orally bioavailable JAK2 inhibitor
for the treatment of RA.
The CIA model is dependent on both T- and B-cell
responses and, as in human RA, depends on the action of
IL-6, demonstrating that CEP-33779 could modulate key
immune cytokines involved in human disease [15,37,38].
Unlike the CIA model, the CAIA model has been shown
not to be entirely dependent on IL-6, as arthritis can still
be induced in mice deficient in this cytokine [39]. How-
ever, surprisingly, robust activity of CEP-33779 was
observed in the CAIA model, sometimes exceeding that of
the standard-of-care agent Dex. The use of tocilizumab
demonstrates how targeting cytokines can directly affect
disease progression without overt immunosuppression [8].
Other small molecules such as INCB028050 have also
been reported to show a similar phenotype, that is, inhibi-
tion of IL-6 and disease without immunosuppression [14].
It is possible that CEP-33779 works similarly to
INCB028050, as both can inhibit immune cellular flux and
cytokine release in acute inflammation mouse models
(that is, delayed hypersensitivity for INCB028050 and the
APM model for CEP-33779) (Figure 5).
Table 2 CIA model joint inflammation histopathology scores
a
Group Proteoglycan
loss
Matrix
erosion
Subchondral
osteolysis
Osteoproliferation Synovial
proliferation
Pannus
formation
Inflammation
degree
Vehicle 3.00 ± 0.00 3.67 ± 1.52 2.50 ± 0.50 2.66 ± 0.57 2.66 ± 0.57 1.66 ± 0.57 2.83 ± 0.28
Compound A 30 mg/kg 2.50 ± 0.57 4.62 ± 0.75 2.75 ± 0.50 2.50 ± 0.40 2.75 ± 0.50 2.37 ± 0.94 2.12 ± 0.25
Compound A 55 mg/kg 1.83 ± 0.76 2.83 ± 1.60 1.33 ± 1.04 1.83 ± 1.15 1.00 ± 0.86 0.83 ± 0.76 0.66 ± 0.57*
Compound A 100 mg/kg 1.83 ± 0.28 2.33 ± 1.52 1.50 ± 0.50 1.66 ± 0.57 1.50 ± 0.86 0.66 ± 1.15 1.33 ± 0.57**
Dex 1.5 mg/kg 2.25 ± 0.95 3.12 ± 2.09 1.37 ± 0.94 1.50 ± 1.08 1.25 ± 0.86 0.75 ± 0.64 1.00 ± 0.81**
Compared to vehicle *P < 0.05 **P < 0.01 ***P < 0.001
aCIA, collagen-induced arthritis. Hematoxylin and eosin- and Safranin O-stained, paraffin wax-embedded carpus and tarsus sections were scored by a board-
certified independent pathologist for the criteria described in Materials and methods. Values are means ± SD for the tarsus only. P values show significance
compared to vehicle group; n = 5 mice per group. Statistical test used was two-way ANOVA. *P < 0.05. **P < 0.01. ***P < 0.001.
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Page 12 of 15JAK2 is responsible for mediating signaling through
several receptors, including those highly implicated in
playing an essential role in autoimmunity and inflamma-
tion, such as the gp130 receptor family members IL-6R
and IL-12Rb and IFNgR2 [40]. Blockade of JAK2 asso-
ciated with these major cytokine receptors may affect
the subsequent expression or production of downstream
cytokines during arthritis and may be responsible for
some of the results shown here. For example, reduction
of cytokines IL-12, IL-2, and TNFa may switch the local
milieu from a strong Th1/Th17 phenotype to a more
immunoregulatory Th2/regulatory T cell phenotype and
lead to disease symptom reduction [41].
Interactions of JAK2 with various immune-related sig-
naling molecules will determine how inhibition of this
kinase may affect other immune cell types and thus the
treatment of other autoinflammatory diseases. Down-
stream JAK2 can interact with STAT5a/b, STAT3,
STAT4, and STAT1 [42]. However, only STAT5a/b are
directly activated by JAK2; STAT4 can be activated via
TYK2, STAT1 can be activated via JAK1, and STAT3
c a nb ea c t i v a t e dv i at h eE G F Rp a t h w a ya n dJ A K 1a n d
Src kinases [28,29]. In addition, several kinases, includ-
ing Tec, Vav1, Fyn, Yes1, and protein tyrosine kinase 2,
also directly interact with JAK2 [43-47]. These kinases
are all involved at some level in the regulation and acti-
vation of immune subsets, especially those of T and B
lymphocytes. Inhibiting JAK2 may have implications
other than just direct inhibition of cytokine signaling.
Downstream inhibition of T- and B-cell activation may
also result from JAK2 inhibition, expanding the possibi-
lities of using a potent inhibitor of this kinase in alter-
nate indications.
Suppressors of the JAK-STAT signaling pathway, sup-
pressors of cytokine signaling (SOCS), also interact
directly with JAK2 (for example, SOCS3) [42,48]. SOCS
proteins act as a negative feedback loop for the JAK-
STAT pathway [49]. Interestingly, the expression of
SOCS is altered in RA patients; levels of SOCS1 and
SOCS3 were shown to be increased in peripheral blood
mononuclear cells (PBMCs) of RA patients [50]. SOCS1
was upregulated in peripheral blood T cells associated
with SOCS3 expression in PBMCs in patients with RA
[ 5 0 ] .S O C S 1w a sa l s os h o w e dt ob eu p r e g u l a t e di nt h e
synovial membranes of patients with RA compared to
patients with osteoarthritis. This suggests that deregula-
tion of JAK2 signaling via effects on SOCS can contri-
bute to RA development and may predict a patient’s
susceptibility to disease development.
Conclusions
This report demonstrates the use of a highly selective
and potent JAK2 inhibitor, CEP-33779, for the treat-
ment of RA using two different mouse models of RA.
Inhibition of disease-promoting cytokine pathways by
CEP-33779 nearly rivaled that of standard-of-care treat-
ments, strongly suggesting the use of this inhibitor in
other IL-6-dependent diseases, such as Crohn’s disease
and ulcerative colitis. CEP-33779 may also have utility
in other diseases dependent on the same pathways such
as systemic lupus erythematosus, inflammatory bowel
disease, psoriasis, and various cancers, including colon,
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Figure 5 Suppression of carrageenan-induced inflammation by
CEP-33779. Balb/c mice were prepared for air pouch initiation (see
Materials and methods) using sterile air. Carrageenan at 1% in saline
solution was injected directly into the pouch, followed immediately
by CEP-33779 or Dex treatment 1 hour later. One hundred
microliters of air pouch fluid were removed 24 hours after
compound administration. (A) Total cell count using 7-
aminoactinomycin D exclusion via flow cytometeric analysis and BD
TruCount beads. (B) Fluid supernatant IL-6 concentration as
determined by Luminex cytokine analysis. (C) Hemoglobin content
was assessed by the Drabkin’s assay. All graphs show means ± SEM.
*P < 0.05 with two-way ANOVA used as the statistical test; n =5
mice per group tested.
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Page 13 of 15prostate, and pancreatic cancer. These results warrant
further preclinical evaluation of selective JAK2 inhibitors
such as CEP-33779.
Additional material
Additional file 1: Total body mass of CEP-33779-treated collagen
antibody-induced arthritis (CAIA) model mice over time. Graph
shows means ± SEM of total body mass of CAIA mice. Female DBA/1
mice were treated with CEP-33779 orally twice daily (b.i.d.) and
dexamethasone (Dex) at 1.5 mg/kg three times weekly, and vehicle
PEG400 + 1% dimethyl sulfoxide (DMSO) was administered orally (p.o.) b.
i.d. Study size shows n ≥ 10 mice per group and n ≥ 5 mice for
individual assays. Black arrow indicates treatment start.
Additional file 2: Reduction of serum interleukin (IL)-6 and IL-4
along with spleen IL-12 in collagen type II (CII)-induced arthritis
(CIA) mice treated with CEP-33779. Female DBA/1 mice were injected
with purified CII in Complete Freund’s Adjuvant (CFA) intradermally (i.d.),
then boosted with CII in Incomplete Freund’s Adjuvant (IFA)
administered subcutaneously (s.c.) on day 21 followed by a day 28
lipopolysaccharide (LPS) injection intraperitoneally (i.p.) to induce CIA.
Mice that scored 1 or better for each paw were considered arthritic and
entered into the study. Treatments started after several days of full
arthritis. CEP-33779 was administered p.o., b.i.d., throughout the
remainder of the experiment. Dex was injected i.p. at 1.5 mg/kg three
times weekly, and vehicle PEG400 + 1% DMSO was administered p.o., b.i.
d. (A) Paw IL-4 concentration from treated CIA mice 4 hours post-oral
dosing. (B) Cytokine IL-12 was measured using Luminex kits (Invitrogen)
for paws and spleens from treated mice 4 hours after p.o. dosing. (C)
Paw IL-6 concentration from treated CIA mice 4 hours after p.o. oral
dosing. Values are means ± SD for the tarsus only. P values show
significance compared to the vehicle group; n = 5 mice per group
scored for both CAIA and CIA groups. The statistical test used was two-
way analysis of variance (ANOVA). *P < 0.05. **P < 0.01. ***P < 0.001.
Study size shows n ≥ 10 mice per group and n ≥ 5 mice for individual
assays. Black arrow indicates treatment start.
Additional file 3: Total body mass of CEP33779-treated CIA model
mice. Graph shows means ± SEM of total body mass of CIA mice.
Female DBA/1 mice were treated with CEP-33779 p.o., b.i.d., Dex at 1.5
mg/kg three times weekly, and vehicle PEG400 + 1% DMSO p.o., b.i.d.
Study size shows n ≥ 10 mice per group and n ≥ 5 mice for individual
assays. Black arrow indicates treatment start.
Additional file 4: No change in serum anti-CII autoantibodies in CIA
mice treated with CEP-33779 over time. Female DBA/1 mice were
injected with purified CII in CFA i.d., then boosted with CII in IFA s.c. on
day 21 followed by a day 28 LPS injection i.p. to induce CIA. Mice that
scored 1 or better for each paw were considered arthritic and entered
into the study. Treatments started after several days of full arthritis. CEP-
33779 was administered p.o., b.i.d., throughout the remainder of the
experiment. Dex was administered i.p. at 1.5 mg/kg three times weekly,
and vehicle PEG400 + 1% DMSO was administered p.o., b.i.d. Serum
testing using an anti-CII autoantibody enzyme-linked immunosorbent
assay (ELISA) is described in Materials and methods and elsewhere [18].
No statistical significance was observed for any group compared to
vehicle using two-way ANOVA. Serum dilution used was a five fold
dilution for all samples, with the diluted sample shown. Graph shows
means ± SEM, n ≥ 10 mice per group tested, with serum collected at
weekly intervals and stored at -80°C until tested. Study size shows n ≥ 10
mice per group and n ≥ 5 mice for individual assays. Black arrow
indicates treatment start.
Abbreviations
CII: type II collagen; CAIA: collagen antibody-induced arthritis; CIA: collagen-
induced arthritis; RA: rheumatoid arthritis; RT: room temperature.
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